Customer voice · Expert interview

How a Singapore public hospital lab chooses and switches diagnostic analyzers now that purchasing is pooled

Format
Modelled interview
As of
October 2026
Market
Singapore
Industry
In-vitro diagnostics
Length
≈ 30 min read
ALPSSingHealthNHG HealthNational University Health SystemMinistry of HealthHealth Sciences AuthorityNational University HospitalMOH Holdings
Modelled interview. Built from KIRA's face-to-face interviews with hospital and commercial laboratory managers, pathology managers and medical technologists in Singapore, and with diagnostics suppliers, set in today's market. How the trade works comes from what those people told our analysts; every figure comes from a public source, marked next to the answer.

Summary

  • Public procurement has moved up a level: the Ministry of Health set up a procurement agency to pool buying across public health institutions where practicable, and its stated aims include several suppliers per contract for resilience. 1 2
  • The lab manager still writes the specification and justifies revenue, cost and turnaround, then the purchase runs through materials management, clinicians, a long trial and a senior panel. 3
  • Most analyzers sit on reagent-rental deals, which is why a lab can move brand when the reagent price is better; the lab that buys the main unit outright does so to avoid reagent mark-ups. 4 5
  • Nobody wants to be the first user, so peer references and a reference site decide more than a brochure, and the real brake on a switch is the middle manager and the technician team. 6 7 8
  • A switch also meets the regulator: a diagnostic lab needs a Healthcare Services Act licence run by a pathology specialist with at least 5 years' laboratory experience, and the Health Sciences Authority issued new analyser-variant guidance on 5 November 2025. 9 10
  • The money pressure is real: the healthcare budget is $21 billion this year and estimated at over $30 billion by 2030, while clusters have been funded by capitation since 2023. 11 1

Transcript

01The buying table is no longer in my hospital

KAKIRA Analyst

You manage a public hospital lab. What would you want a supplier to understand first about how analyzers get bought in Singapore today?

EXExpert

That the table has moved up, and that most suppliers have not caught up with it. The Ministry of Health set up the Agency of Logistics and Procurement Services to pool buying across the public health institutions where practicable, and it also wants contracts with several suppliers so that supply is more resilient. 1 SingHealth's own page says the agency will enable group contracts at the national level, with cluster-based or institution-based contracts continuing where needed. 2

Notice the words where practicable and where needed. They leave room, and I cannot tell you where the line falls for a given analyzer, it depends on the item and on the year. What I can tell you is that a salesman who still thinks one hospital's lab manager is the whole decision will spend a year talking to the wrong person. 1

KAKIRA Analyst

So does the pool mean the lab no longer chooses?

EXExpert

We still choose what we can live with. A public hospital purchase has always gone through a specification, a shortlist from materials management, input from the clinicians, a trial that can run up to a year, and a senior panel, and I have to justify revenue, cost and turnaround on paper. 3 The pool adds a step above that chain; it does not remove the chain. Whoever signs at the top still needs a specification that my bench can run on a Monday morning with a full rack. 3

And do not forget who the public system is. It is run by three healthcare clusters, one for the central, one for the western and one for the eastern part of the island, and the procurement agency is described as the body that drives public healthcare procurement for all of them. 12 A supplier who knows only one cluster knows a third of the picture. 12

02Reagent rental, and why a brand can move

KAKIRA Analyst

How do public labs actually pay for analyzers? Do you buy them?

EXExpert

Mostly we do not buy; the analyzer is placed with the lab and we pay through the reagents. Most analyzers are on reagent-rental deals rather than bought outright, and that is exactly why a lab can switch brand fairly easily when another supplier offers a better reagent price. 4 The machine is not the lock-in. The reagent contract is. 4

There is a twist that outsiders miss. Some large hospitals buy the main analyzer outright to avoid reagent mark-ups, and rent only the backup unit that is used less. 5 So when you quote, ask which unit it is, the one that runs all day or the one that sits waiting for a breakdown. The sensible price for each is not the same. 5

KAKIRA Analyst

Has the way budgets work changed how you buy?

EXExpert

A lot, and I am glad of it. Under old fixed budgets, labs spent to the limit to protect next year's allocation, and that inflated the prices we paid. 13 Since 2023 the public clusters have been funded by capitation, which the Ministry says encourages value through productivity gains. 1 I will not claim the old habit has vanished from every corner, but the incentive points the other way now. 13

Asked in Parliament about a systematic productivity cut of 1% to 2% a year, the Ministry replied that such extraction is generally not practised in healthcare internationally. 1 For me that is a signal: the pressure will come through tenders and benchmarks, not through a blanket squeeze. 14

03How a new analyzer gets approved

KAKIRA Analyst

Walk me through a real approval. Where does it usually get stuck?

EXExpert

It starts with me writing the case: which tests, what volume, what turnaround, what it does to staff time. Staff are the largest part of my running cost and reagents the next, so automation is justified mainly by the manpower it saves. 15 Then it goes to materials management for the shortlist, the clinicians have their say, we trial, and a senior panel decides. 3

Where it sticks is the trial and the people. A technician team may resist a new automated system because of the retraining or because they fear for their jobs, and a middle manager does not want the extra work of a switch. 8 7 So a good supplier trains the night shift first and talks to my director about cost and profit, not only to me. 7

KAKIRA Analyst

What does automation look like in a big public lab today?

EXExpert

Look at what the large hospitals say about themselves. The core laboratory at National University Hospital describes itself as highly automated with round-the-clock service, with a track doing centrifugation, aliquoting and archival for all samples, and an automated chemistry and haematology track. 16 That is the standard a supplier is measured against in a big hospital. 16

In my experience the track is where the argument about brands ends up. If your analyzer cannot sit on our line with a single interface, the conversation is over before the price. Labs are consolidating to one or two major brands with integrated systems, and only the largest reference hospitals keep some diversity. 17

04References, trials and the first user problem

KAKIRA Analyst

What persuades you faster, a good brochure or a good colleague?

EXExpert

A colleague, every time. Most labs do not want to be the first user of a new analyzer, and I am no different, so I ask which hospital has run it, for how long, and what broke. 6 Peer references weigh heavily. A supplier who has one respected lab running its system on a long contract has a reference site, and that is how the others open. 18

Suppliers know this. Some place an analyzer free to win a flagship account, because the reference value is worth more to them than the margin. I do not mind, as long as the reagent contract that follows is fair and the service does not drop once they have won. 18

KAKIRA Analyst

Would you rather upgrade or switch brand?

EXExpert

Upgrade, nearly always. We would rather upgrade what we have than switch, and we want a supplier that acts as a partner, not just a vendor. 19 A switch costs me validation, retraining and a bad month, so I need a clear gain before I put the roster through it. 8

In haematology and routine chemistry the equipment sits in a replacement cycle of several years, so the supplier who wins is usually the one who takes share at replacement time, not the one who brings a new idea. 20 And a supplier who bundles its strong segment with a weaker one at attractive combined terms gets my attention, though I check what the weaker analyzer will cost me in the second year. 21

05Distributor or manufacturer

KAKIRA Analyst

Do you care whether a supplier sells direct or through a distributor?

EXExpert

I care a great deal. Almost all of us dislike buying through distributors, because of poor responsiveness and thin technical knowledge, and we prefer to deal with the manufacturer directly. 22 When an analyzer stops, I want an engineer who knows it, not a person who passes the message on. 22

Be careful when you change distributor, too. A change of distributor can cost a supplier share, because the people who know the bench and its quirks leave with the old contract. 22 If you are a foreign maker, the model matters more than the logo. A good partner who answers on the first ring will do better than a famous brand with a slow one. 19

KAKIRA Analyst

Does the national pool change that?

EXExpert

It makes the commercial terms more visible, since the agency buys for many institutions, and it pushes suppliers towards a single point of contact. 2 But the agency's stated aim is also several suppliers per contract for resilience. 1 I read that as: you will not get everything, so be the supplier I can call at night. 1

06What the regulator asks before a switch

KAKIRA Analyst

What does the law ask of the lab and of the supplier when you change analyzers?

EXExpert

Two layers. For the lab, a clinical laboratory service licence under the Healthcare Services Act is needed for testing that diagnoses a condition, disease or injury, and the clinical governance officer must be a registered specialist in pathology or haematology with at least 5 years' relevant laboratory experience. 9 The licence fee is $1,016 for each mode of service delivery. 9 Simple point-of-care tests, like glucose or pregnancy tests in an outpatient service, are exempt. 9

For the supplier, the Health Sciences Authority has a risk-class system. Class A devices are exempt from registration but need a product notification, and for classes B to D there are full, abridged and expedited routes, depending on the approvals the product already holds overseas. 23 A route that needs marketing in the reference country for at least 3 years will not suit a new product. 23

KAKIRA Analyst

Anything recent a supplier should know?

EXExpert

On 5 November 2025 the Health Sciences Authority issued guidance on which variants of an IVD analyser may be grouped under its family framework. Variants that change diagnostic functions need separate listing, while acceptable variants can be grouped under existing rules. 10 If your range has several versions of the same analyzer, ask your regulatory team which ones are the same family before you tell me they are interchangeable. 10

Our accreditation matters in the same way. National University Hospital's laboratory cites ISO 15189:2022 accreditation, and a new analyzer has to fit inside the quality system that holds it. 16 I check that at the start, because a validation that does not fit costs me weeks. 16

07Advice to a newcomer, and what worries me

KAKIRA Analyst

A new maker wants to enter Singapore's public hospital labs. What would you tell them?

EXExpert

Start with a reference, not a price list. Find one lab that will run your system and let it be seen. 6 Sell the case that I can take to my director: manpower saved, turnaround, cost per result. 15 And plan for the long trial, because the process can run for up to a year before a panel sits. 3

Have your own people on the ground, or a partner who really knows the equipment, and make it plain who answers the phone. 22 Do not promise a clean switch. Be honest about the validation work and the retraining, because the technicians will tell me if you are not. 8

KAKIRA Analyst

What would change your mind about how you buy, and what worries you?

EXExpert

If the pooled contracts started to carry a single winner across the whole system, I would worry about resilience, and I would say so, because the agency itself says it wants several suppliers. 1 What would change my mind is the opposite: if a pooled price came with real service, I would gladly give up some of my own negotiating. 2

What worries me is the bill. This year's healthcare budget is $21 billion, second only to defence, and it is estimated at over $30 billion by 2030, so someone will look at every line, including mine. 11 The public system's spending on drugs slowed from about 10% before FY2021 to 5% in FY2023, and I expect the same eye on diagnostics. 14 I would rather show my numbers first than have them asked for. 3

Sources and basis

  1. 1
    Written parliamentary reply for the sitting of 14 October 2025: the Ministry of Health set up the Agency of Logistics and Procurement Services to pool procurement across public health institutions where practicable; contracts with several suppliers are also meant to improve supply resilience; since 2023 the public healthcare clusters have been funded by capitation, which the Ministry says encourages value through productivity gains and investment in prevention; the question put to the Ministry referred to a systematic productivity extraction factor of 1% to 2% annually, and the reply said such extraction is generally not practised in the healthcare industry internationally
    Public source · Ministry of Health, written parliamentary reply, 14 Oct 2025 · link
  2. 2
    ALPS Pte Ltd buys drugs, medical and non-medical supplies and equipment, and services for SingHealth and its public healthcare institutions; the page says ALPS will enable group contracts at the national level, with cluster-based or institution-based contracts continuing where needed (the organisation's own statement)
    Public source · SingHealth procurement page, About us, accessed Oct 2026 · link
  3. 3
    A public hospital purchase goes through a specification, shortlisting by materials management, clinician input, a trial that can run up to a year and a senior panel; the lab manager must justify revenue, cost and turnaround
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  4. 4
    Most analyzers are placed on reagent-rental deals rather than bought outright, so laboratories can switch brands relatively easily when offered better reagent prices
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  5. 5
    Some large hospitals buy the main analyzer outright to avoid reagent mark-ups but rent the under-used backup unit
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  6. 6
    Laboratories avoid being the first user of a new analyzer; references from peer laboratories weigh heavily
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  7. 7
    The real obstacle for a supplier is the middle manager who does not want the extra work of switching brands, so suppliers also sell to senior management on cost and profitability
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories and suppliers
  8. 8
    Laboratory technicians may resist new automated systems because of the retraining effort or fear for their jobs
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  9. 9
    Healthcare Services Act page on the Clinical Laboratory Service: a licence is needed for testing used to diagnose a condition, disease or injury; simple in vitro diagnostic tests incidental to care, such as point-of-care glucose or pregnancy testing in an outpatient medical service, are exempt; Specified Services include Chemical Pathology, Hematology and Immunology; the Clinical Governance Officer must be a registered specialist in pathology or haematology with at least 5 years' relevant laboratory experience; the licence fee is $1,016 for each mode of service delivery
    Public source · Ministry of Health, Healthcare Services Act site, page last updated 26 Mar 2026, accessed Oct 2026 · link
  10. 10
    Health Sciences Authority issued guidance on 5 November 2025 on acceptable and unacceptable variants of IVD analysers under its FAMILY grouping framework: variants that change diagnostic functions need separate listing, while acceptable variants can be grouped under existing rules (page updated Dec 2025)
    Public source · RegAsk, reporting on Health Sciences Authority guidance of 5 Nov 2025 · link
  11. 11
    Minister for Health, Committee of Supply debate, 7 March 2025: this year's healthcare budget is $21 billion, second behind the Ministry of Defence; the annual health budget was about $9 billion in 2015; by 2030 it is estimated to be over $30 billion
    Public source · Ministry of Health, Minister's Committee of Supply speech, 7 Mar 2025 · link
  12. 12
    The public healthcare system is geographically structured and managed by 3 healthcare clusters: NHG Health (central), National University Health System (western) and Singapore Health Services (eastern); ALPS is described as driving public healthcare procurement by strategically sourcing, contracting and enabling reliable supply (the group's own statement)
    Public source · MOH Holdings, Our entities page, accessed Oct 2026 · link
  13. 13
    Under fixed budgets laboratories spent to the limit to protect the next year's budget, which inflated the prices paid
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  14. 14
    Written parliamentary replies for the sitting of 8 April 2025: Health Technology Assessments are used to fund and encourage clinically and cost-effective health technologies; drug spending growth in the public system slowed from about 10% before FY2021 to 5% in FY2023; a value-driven care programme in the public healthcare clusters tracks and benchmarks quality and cost across common conditions; fee benchmarks cover close to 2,200 common procedures and conditions; national healthcare spending was under 5% of GDP as of 2022
    Public source · Ministry of Health, written parliamentary replies, 8 Apr 2025 · link
  15. 15
    Staff are the largest part of a laboratory's running cost and reagents and consumables the next; automation is justified mainly by the manpower it saves
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  16. 16
    The core laboratory at National University Hospital is described as highly automated with round-the-clock service; its automation provides centrifugation, aliquoting and archival for all samples; it has an automated chemistry and haematology track system; the department cites ISO 15189:2022 accreditation (the hospital's own statement)
    Public source · National University Hospital, Laboratory Medicine page, accessed Oct 2026 · link
  17. 17
    Laboratories are consolidating to one or two major brands with integrated systems and a single interface, while the largest reference hospitals keep some diversity
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  18. 18
    Suppliers use a first major customer as a reference site to unlock other laboratories, and some place analyzers free to win flagship accounts
    KIRA field interviews · KIRA field interviews, Singapore diagnostics suppliers
  19. 19
    Laboratories would rather upgrade what they have than switch brand, and want a supplier that acts as a partner, not just a vendor
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  20. 20
    Hematology and routine chemistry are replacement markets on multi-year equipment cycles; growth there comes from taking share
    KIRA field interviews · KIRA field interviews, Singapore diagnostics suppliers
  21. 21
    Bundling a strong product segment with a weaker one at attractive combined terms is a common tactic to enter a laboratory's immunoassay business
    KIRA field interviews · KIRA field interviews, Singapore diagnostics suppliers
  22. 22
    Almost all laboratories dislike buying through distributors, citing poor responsiveness and technical knowledge, and prefer to deal with the manufacturer directly; a change of distributor can cost a supplier share
    KIRA field interviews · KIRA field interviews, Singapore hospital laboratories
  23. 23
    Medical device registration overview: Class A medical devices are exempted from product registration, but a product notification in SHARE is still required; for Class B to D there is a full route (no prior approval from an overseas reference agency), an abridged route (approval from at least one overseas reference agency) and expedited routes; the Class C expedited route ECR-1 needs one agency approval plus marketing for at least 3 years in that agency's jurisdiction, while ECR-2 and EDR need approval from at least 2 reference agencies; IVD assays intended for HIV testing (excluding IVD analysers) cannot use the expedited EDR route
    Public source · Health Sciences Authority, medical device registration overview, page last updated 13 Mar 2026, accessed Oct 2026 · link

Key points

Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.

More on Medical devices in Singapore · Medical devices: pricing across Asia · Medical devices: why buyers switch across Asia · Medical devices: who decides across Asia · Medical devices: competition across Asia